Conference Coverage

ASCO Conference Coverage
ASCO Conference Coverage
06/09/2025
Miranda Manier, BA
A cross-sectional study identifies key predictors of peritonitis in ovarian cancer hospitalizations, highlighting early intervention opportunities.
06/09/2025
Conference Coverage
Conference Coverage
06/06/2025
Anthony Calabro, MA
Patients with breast cancer and coexisting chronic lymphocytic leukemia (CLL) present with more advanced disease and poorer survival compared with those without CLL, according to the results of a...
06/06/2025
Conference Coverage
Conference Coverage
06/06/2025
Anthony Calabro, MA
Patients with breast cancer and coexisting chronic lymphocytic leukemia (CLL) present with more advanced disease and poorer survival compared with those without CLL, according to the results of a...
06/06/2025
Conference Coverage
Conference Coverage
06/06/2025
Anthony Calabro, MA
Patients with breast cancer and coexisting chronic lymphocytic leukemia (CLL) present with more advanced disease and poorer survival compared with those without CLL, according to the results of a...
06/06/2025
Conference Coverage
Conference Coverage
06/06/2025
Anthony Calabro, MA
Patients with breast cancer and coexisting chronic lymphocytic leukemia (CLL) present with more advanced disease and poorer survival compared with those without CLL, according to the results of a...
06/06/2025
Conference Coverage
Conference Coverage
06/06/2025
Anthony Calabro, MA
Patients with breast cancer and coexisting chronic lymphocytic leukemia (CLL) present with more advanced disease and poorer survival compared with those without CLL, according to the results of a...
06/06/2025
ASCO Conference Coverage
ASCO Conference Coverage
06/05/2025
Anthony Calabro, MA
Researchers found that the combination of benmelstobart, chemotherapy, and anlotinib yields improved response and progression-free survival in patients with advanced or recurrent endometrial cancer,...
06/05/2025
ASCO Conference Coverage
ASCO Conference Coverage
06/05/2025
Anthony Calabro, MA
Researchers found that the combination of benmelstobart, chemotherapy, and anlotinib yields improved response and progression-free survival in patients with advanced or recurrent endometrial cancer,...
06/05/2025
ASCO Conference Coverage
ASCO Conference Coverage
06/05/2025
Anthony Calabro, MA
Researchers found that the combination of benmelstobart, chemotherapy, and anlotinib yields improved response and progression-free survival in patients with advanced or recurrent endometrial cancer,...
06/05/2025
ASCO Conference Coverage
ASCO Conference Coverage
06/05/2025
Anthony Calabro, MA
Researchers found that the combination of benmelstobart, chemotherapy, and anlotinib yields improved response and progression-free survival in patients with advanced or recurrent endometrial cancer,...
06/05/2025